0001104659-20-132152.txt : 20201203
0001104659-20-132152.hdr.sgml : 20201203
20201203214103
ACCESSION NUMBER: 0001104659-20-132152
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201201
FILED AS OF DATE: 20201203
DATE AS OF CHANGE: 20201203
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bernstein Bruce
CENTRAL INDEX KEY: 0001665472
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38045
FILM NUMBER: 201368479
MAIL ADDRESS:
STREET 1: 780 THIRD AVENUE, 12TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10017
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Neurotrope, Inc.
CENTRAL INDEX KEY: 0001513856
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 463522381
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1185 AVENUE OF THE AMERICAS
STREET 2: 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
BUSINESS PHONE: (973) 242-0005
MAIL ADDRESS:
STREET 1: 1185 AVENUE OF THE AMERICAS
STREET 2: 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
FORMER COMPANY:
FORMER CONFORMED NAME: BlueFlash Communications, Inc.
DATE OF NAME CHANGE: 20110223
4
1
tm2037705d5_4.xml
OWNERSHIP DOCUMENT
X0306
4
2020-12-01
0
0001513856
Neurotrope, Inc.
NTRP
0001665472
Bernstein Bruce
C/O NEUROTROPE, INC.
1185 AVENUE OF THE AMERICAS, 3RD FLOOR
NEW YORK
NY
10036
1
0
0
0
Common Stock
2020-12-01
4
D
0
1565
D
0
D
Stock Option (right to buy)
16.32
2020-12-01
4
D
0
7813
D
Common Stock
7813
0
D
Stock Option (right to buy)
10.56
2020-12-01
4
D
0
15535
D
Common Stock
15535
0
D
Stock Option (right to buy)
19.10
2020-12-01
4
D
0
10000
D
Common Stock
10000
0
D
Stock Option (right to buy)
8.912
2020-12-01
4
D
0
10000
D
Common Stock
10000
0
D
Stock Option (right to buy)
3.93
2020-12-01
4
D
0
25000
D
Common Stock
25000
0
D
Stock Option (right to buy)
4.06
2020-12-01
4
D
0
10000
D
Common Stock
10000
0
D
Stock Option (right to buy)
0.8203
2020-12-01
4
D
0
10000
D
Common Stock
10000
0
D
Stock Option (right to buy)
0.972
2020-12-01
4
D
0
72500
D
Common Stock
72500
0
D
Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the common stock was disposed of as follows: the reporting person received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope common stock held.
Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
/s/ Robert Weinstein, Attorney-in-Fact
2020-12-03